Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F7 | P08709 | 4/20 | 0.81 |
| ▸ | F3 | P13726 | 4/20 | 0.81 |
| ▸ | C1R | P00736 | 6/20 | 0.47 |
| ▸ | HPN | P05981 | 1/20 | 0.45 |
| ▸ | ELANE | P08246 | 3/20 | 0.43 |
| ▸ | APEX1 | P27695 | 1/20 | 0.41 |
| ▸ | F10 | P00742 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL915758 | 0.90 | F7 (1.00) | F7F3C1RHPNELANE | |
| SCHEMBL914467 | 0.86 | C1R (0.67) | F7F3C1RELANEAPEX1 | |
| SCHEMBL3452610 | 0.82 | ELANE (0.60) | F7F3C1RHPNELANE | |
| SCHEMBL914399 | 0.81 | F7 (0.58) | F7F3C1RHPNELANE | |
| SCHEMBL914143 | 0.81 | KDM4E (0.59) | F7F3C1RHPNELANE | |
| SCHEMBL913631 | 0.80 | F7 (0.67) | F7F3C1RHPNELANE | |
| SCHEMBL7320508 | 0.79 | C1R (0.72) | F7F3C1RELANEF10 | |
| SCHEMBL914071 | 0.78 | C1R (0.61) | F7F3C1RHPNELANE | |
| SCHEMBL913408 | 0.77 | F7 (0.82) | F7F3C1RHPNELANE | |
| SCHEMBL10741223 | 0.77 | HPN (0.61) | F7F3C1RHPNELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6180625-B1 | MODULATING AND NORMALIZING AN IMPAIRED HAEMOSTATIC BALANCE IN A MAMMAL, WHICH METHOD COMPRISES ADMINISTERING AN EFFECTIVE AMOUNT OF NOVEL BENZOXAZIN DERIVATIVES; ANTICOAGULANTS | NOVO NORDISK A/S (DK) | 2001-01-30 | — | — | US | claimed |
| US-7872052-B2 | Use of heterocyclic compounds as SCCE inhibitors | AREXIS AB (SE) | 2011-01-18 | — | — | US | disclosed |
| US-20060258651-A1 | Use of heterocyclic compounds as scce inhibitors | QUANTUM LTO HOLDINGS, LLC | 2006-11-16 | — | — | US | disclosed |
| EP-1631295-A2 | USE OF FUSED HETEROCYCLIC COMPOUNDS AS SCCE INHIBITORS FOR THE TREATMENT OF SKIN CONDITIONS OR CANCER | Arexis AB (SE) | 2006-03-08 | — | — | EP | disclosed |
| WO-2004108139-A2 | USE OF FUSED HETEROCYCLIC COMPOUNDS AS SCCE INHIBITORS FOR THE TREATMENT OF SKIN CONDITIONS OR CANCER | AREXIS AB (SE) | 2004-12-16 | — | — | WO | disclosed |
| US-6180625-B1 | MODULATING AND NORMALIZING AN IMPAIRED HAEMOSTATIC BALANCE IN A MAMMAL, WHICH METHOD COMPRISES ADMINISTERING AN EFFECTIVE AMOUNT OF NOVEL BENZOXAZIN DERIVATIVES; ANTICOAGULANTS | NOVO NORDISK A/S (DK) | 2001-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258651-A1 | Use of heterocyclic compounds as scce inhibitors | RCE1, CTSE, SPINT2 | F7 3152/4885F3 1856/4885C1R 202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.